A device for plasma treatment of biological tissue can comprise a hollow needlelike tubular section with a distal end for applying a light-induced plasma to the tissue, wherein the tubular section comprises subsequent to the distal end an inner plasma chamber configured for generating therein a light-induced plasma. In one embodiment, the plasma chamber is communicatively coupled with a distal, central axial aperture in the distal end, and adjoins, within the tubular section, a light injection section for injecting light, in particular laser light pulses, into the plasma chamber for plasma generation.

An ophthalmic phototherapy device and associated treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The device includes a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

To treat corneal ectatic disorders, systems and methods can precisely apply photoactivating light to specified areas of a cornea treated with a cross-linking agent. An example system includes a light source that provides a photoactivating light to photoactivate a cross-linking agent applied to an eye. The system includes optical element(s) that transmit the photoactivating light to the eye according to a pattern defined by a plurality of treatment zones. The treatment zones are delivered to different respective areas on the eye. The plurality of treatment zones includes at least a first treatment zone and a second treatment zone. The first treatment zone provides a first dose of the photoactivating light. The second treatment zone provides a second dose of the photoactivating light. The first dose is greater than the second dose. The first treatment zone is disposed within an inner boundary of the second treatment zone.

Disorders of the eye can be treated by photobiomodulation therapy according to a device designed to direct light into a patient's eye, no matter the configuration of the eye. The device, including a printed circuit board that includes an array of light delivery devices and a heat sink lens, can be placed proximal to the patient's eye. The light delivery devices can be powered to generate light. The light can be directed into the patient's eye regardless of a position of the patient's eye.

Methods and apparatus for the treatment of the eye to reduce pain can treat at least an outer region of the tissue so as to denervate nerves extending into the inner region and reduce the pain. For example, the cornea of the eye may comprise an inner region having an epithelial defect, and an outer portion of the cornea can be treated to reduce pain of the epithelial defect. The outer portion of the cornea can be treated to denervate nerves extending from the outer portion to the inner portion. The outer portion can be treated in many ways to denervate the nerve, for example with one or more of heat, cold or a denervating noxious substance such as capsaicin. The denervation of the nerve can be reversible, such that corneal innervation can return following treatment.

An ocular protection device and treatment methods are disclosed. The device has a corneal shield with an attached handle. The handle may be used to move the corneal shield to better protect the eye from various treatment modalities. The handle may also be used to place tension on the eyelid to counteract the forces imposed by a treatment handpiece. A procedure for treating the eye is disclosed where multiple passes with a treatment handpiece cause a gradual increase in the temperature of an eyelid up to a treatment temperature. Once the treatment temperature has been met, occlusions in the Meibomian glands of the eyelid may be expressed. The procedure may be repeated recursively until a desired level of expression has been achieved.

A magnetic positioning system and related method for automated or assisted eye-docking in ophthalmic surgery. The system includes a magnetic field sensing system on a laser head and a magnet on a patient interface to be mounted on the patient's eye. The magnetic field sensing system includes four magnetic field sensors located on a horizontal plane for detecting the magnetic field of the magnet, where one pair of sensors are located along the X direction at equal distances from the optical axis of the laser head and another pair are located along the Y direction at equal distances from the optical axis. Based on relative magnitudes of the magnetic field detected by each pair of sensors, the magnetic field sensing system determines whether the patient interface is centered on the optical axis. The system controls the laser head to move toward the patient interface until the latter is centered on the optical axis.

Systems, methods, and compositions generate cross-linking activity for treatment of eye disorders. Various agents, additives, buffers, etc., may be employed in formulations with a cross-linking agent to enhance treatment. For example, a composition for applying treatment to a cornea of an eye includes a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photo-activating light. The composition also includes an iron additive and citrate buffer. In some cases, the cross-linking agent may include riboflavin. In other cases, the iron additive may include FeSO.sub.4. In further cases, the iron additive may be dissolved in the citrate buffer.

A change in the response of the cornea to ultrasonic energy directed into the cornea is monitored during irradiation of the cornea to bring about corneal crosslinking. Because the change in ultrasonic response is correlated with the degree of crosslinking achieved, a desired degree of crosslinking can be achieved by terminating the irradiation when the change reaches a threshold. The change in ultrasonic response can be determined by taking a baseline measurement before irradiation and additional measurements during irradiation using the same ultrasonic transducer (47). The transducers may be carried on a device (30) resembling a contact lens which overlies the eye and which transmits the light used in the irradiation step to the eye.

The present invention relates to an ultrasound contrast agent for use in treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein the ultrasound contrast agent is administered just before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam. The present invention further relates to a therapeutically active agent for use in treating a retina disorder in a human, wherein the therapeutically active agent is to be delivered in combination with an ultrasound contrast agent, which is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam in order to transiently disrupting the blood-retinal barrier (BRB) of the human, to allow the therapeutically active agent to cross the BRB and to target the retina. The present invention also relates to an eye ultrasound delivery device that may be used to treat a retina disorder.